These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
340 related articles for article (PubMed ID: 27111278)
1. Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas. Mukaigawa T; Hayashi R; Hashimoto K; Ugumori T; Hato N; Fujii S J Surg Oncol; 2016 Jul; 114(1):36-43. PubMed ID: 27111278 [TBL] [Abstract][Full Text] [Related]
2. Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors. Zhang L; Qiu M; Jin Y; Ji J; Li B; Wang X; Yan S; Xu R; Yang D Int J Clin Exp Pathol; 2015; 8(9):11084-91. PubMed ID: 26617827 [TBL] [Abstract][Full Text] [Related]
3. Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas. Zeng J; Zhang XK; Chen HD; Zhong ZH; Wu QL; Lin SX Oncotarget; 2016 Feb; 7(8):8944-55. PubMed ID: 26771840 [TBL] [Abstract][Full Text] [Related]
4. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma. Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759 [TBL] [Abstract][Full Text] [Related]
6. Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas. Nakano T; Takizawa K; Uezato A; Taguchi K; Toh S; Masuda M Oral Oncol; 2019 Mar; 90():30-37. PubMed ID: 30846173 [TBL] [Abstract][Full Text] [Related]
7. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma. Yang CY; Lin MW; Chang YL; Wu CT; Yang PC Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614 [TBL] [Abstract][Full Text] [Related]
8. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers. Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388 [TBL] [Abstract][Full Text] [Related]
9. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Cooper WA; Tran T; Vilain RE; Madore J; Selinger CI; Kohonen-Corish M; Yip P; Yu B; O'Toole SA; McCaughan BC; Yearley JH; Horvath LG; Kao S; Boyer M; Scolyer RA Lung Cancer; 2015 Aug; 89(2):181-8. PubMed ID: 26024796 [TBL] [Abstract][Full Text] [Related]
10. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas. Kim S; Kim MY; Koh J; Go H; Lee DS; Jeon YK; Chung DH Eur J Cancer; 2015 Nov; 51(17):2698-707. PubMed ID: 26329973 [TBL] [Abstract][Full Text] [Related]
11. Favorable Disease-free Survival Associated with Programmed Death Ligand 1 Expression in Patients with Surgically Resected Small-cell Lung Cancer. Toyokawa G; Takada K; Haratake N; Takamori S; Akamine T; Katsura M; Fujishita T; Shoji F; Okamoto T; Oda Y; Maehara Y Anticancer Res; 2016 Aug; 36(8):4329-36. PubMed ID: 27466552 [TBL] [Abstract][Full Text] [Related]
12. Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer. Ishii H; Azuma K; Kawahara A; Yamada K; Imamura Y; Tokito T; Kinoshita T; Kage M; Hoshino T J Thorac Oncol; 2015 Mar; 10(3):426-30. PubMed ID: 25384063 [TBL] [Abstract][Full Text] [Related]
13. Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability. Cho J; Lee J; Bang H; Kim ST; Park SH; An JY; Choi MG; Lee JH; Sohn TS; Bae JM; Kang WK; Kim S; Kim KM Oncotarget; 2017 Feb; 8(8):13320-13328. PubMed ID: 28076847 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma. Vassilakopoulou M; Avgeris M; Velcheti V; Kotoula V; Rampias T; Chatzopoulos K; Perisanidis C; Kontos CK; Giotakis AI; Scorilas A; Rimm D; Sasaki C; Fountzilas G; Psyrri A Clin Cancer Res; 2016 Feb; 22(3):704-13. PubMed ID: 26408403 [TBL] [Abstract][Full Text] [Related]
15. Diffuse high intensity PD-L1 staining in thymic epithelial tumors. Padda SK; Riess JW; Schwartz EJ; Tian L; Kohrt HE; Neal JW; West RB; Wakelee HA J Thorac Oncol; 2015 Mar; 10(3):500-8. PubMed ID: 25402569 [TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status. Shin SJ; Jeon YK; Kim PJ; Cho YM; Koh J; Chung DH; Go H Ann Surg Oncol; 2016 Feb; 23(2):694-702. PubMed ID: 26464193 [TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma. Chen K; Cheng G; Zhang F; Zhang N; Li D; Jin J; Wu J; Ying L; Mao W; Su D Oncotarget; 2016 May; 7(21):30772-80. PubMed ID: 27120796 [TBL] [Abstract][Full Text] [Related]